Sequenom is a life sciences company focused on improving
healthcare through revolutionary genetic analysis solutions. The company
develops innovative technology, products, and diagnostic tests that target and
serve discovery and clinical research, and molecular diagnostic markets.
Applications include translation research, oncology, agricultural genomics, and
in vitro diagnostics.
The company reported today that earlier this month its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine or Sequenom CMM, surpassed 100,000 MaterniT21 PLUS test samples processed since the launch of its laboratory developed test in October 2011.
The MaterniT21 PLUS test was the first commercial non-invasive prenatal test of its kind for the detection of a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down Syndrome. This test has shown a high degree of accuracy and is offered by Sequenom CMM to pregnant women at high risk of carrying a fetus with fetal aneuploidy. It can be used as early as 10 weeks gestation.
In response to the rapid volume growth and adoption of the test by the obstetrics community, Sequenom CMM is in the process of increasing its testing capacity by completing the validation and licensure of an additional location in North Carolina. This location is expected to be operational in the second half of 2013 and will increase the company’s total capacity to handle the current 200,000 test samples per year to a minimum of 300,000 test samples a year.
For additional information about Sequenom, please visit www.sequenom.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html